Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Stuttgart – page 22

982 clinical trials in Stuttgart, Germany across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Stuttgart at a glance
982
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

982 trials in Stuttgart

Open in trial search

Alpha-1 antitrypsin deficiency

Recruiting

Study on the Safety of Self-Infusion Therapy with Human Alpha1-Proteinase Inhibitor for Patients with Severe Alpha-1 Antitrypsin Deficiency

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Grifols S.A.

Malignant peritoneal neoplasm+2

Recruiting

Comparison of niraparib alone versus niraparib with bevacizumab in patients with newly diagnosed advanced ovarian cancer after chemotherapy with carboplatin and paclitaxel

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AGO Research GmbH

Cognitive disorder

Recruiting

Study on the Long-Term Effects of Gadoxetic Acid, Gadoteridol, and Gadobenate Dimeglumine on Motor and Cognitive Functions in Healthy Adults

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Gadobutrol
  • Sponsor:Iqvia Rds France

Endometrial cancer+13

Recruiting

Study on Ifinatamab Deruxtecan for Patients with Recurrent or Metastatic Solid Tumors

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ifinatamab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Neonatal alloimmune thrombocytopenia

Recruiting

Study of Nipocalimab or IVIG for Pregnant Women at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Colon cancer stage III+1

Recruiting

Study on Pre-Operative Chemotherapy with Disodium Folinate, Oxaliplatin, and Fluorouracil for Patients with Advanced Resectable Colon Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Sickle cell disease

Recruiting

Study of GBT021601 for Adults and Children with Sickle Cell Disease

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Sponsor:Global Blood Therapeutics Inc.

T-cell type acute leukaemia

Recruiting

Study on the Safety and Effectiveness of Isatuximab and Drug Combination for Adults with Relapsed or Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Goethe University Frankfurt

Hormone-refractory prostate cancer+1

Recruiting

Study of Opevesostat, Olaparib, and Cabazitaxel in Patients with Advanced Prostate Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer stage III

Recruiting

Study of accelerated chemoradiotherapy followed by durvalumab treatment in patients with locally advanced non-small-cell lung cancer (NSCLC) using PET imaging guidance

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:TheraOp gGmbH

Plasma cell myeloma

Recruiting

Study Comparing Elranatamab, Daratumumab, and Lenalidomide with Daratumumab, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Pfizer Inc.

Neonatal respiratory distress syndrome

Recruiting

Study comparing prophylactic versus selective surfactant (poractant alfa, phospholipid fraction) administration in preterm infants with respiratory distress syndrome aged 25-30 weeks

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Poractant Alfa
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Other cities in Germany

The busiest research cities in the country

All 504 cities in Germany

Clinical research in Stuttgart

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on metastatic prostate cancer, diffuse large B-cell lymphoma, and bladder cancer treatments. Studies evaluate novel therapeutic approaches including targeted therapies and immunotherapy combinations.

  • Advanced Cancer Treatments
  • Immunotherapy Studies
  • Novel Drug Combinations

Several trials investigating breakthrough treatments for various forms of leukemia and solid tumors.

02 Immunology and Vaccines

Research focusing on cytomegalovirus prevention and influenza vaccination in different age groups. Studies evaluate innovative vaccine formulations and immune responses.

  • Vaccine Development
  • Immune Response Studies
  • Preventive Medicine

Trials aim to enhance vaccine efficacy and improve protection against infectious diseases.

03 Metabolic and Eye Disorders

Studies addressing weight management and various eye conditions including retinal disorders. Research includes innovative treatments for macular degeneration and vision preservation.

  • Weight Management Therapies
  • Retinal Disease Treatment
  • Vision Preservation

Focus on developing treatments that improve patient outcomes and quality of life.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.